Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2010-08-22 Report Publication Anno…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
US analyst values Phylogica at significant premium to market 1
Report Publication Announcement Classification · 95% confidence The document is a short announcement dated 23 August 2010 from Phylogica Limited, stating that a research report by RB Milestone Group has been prepared and is available on the company's website. The text does not contain the research report itself, nor any financial data or detailed analysis. It is essentially a notification about the availability of a third-party research report commissioned by the company. The document length is only 1323 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2010-08-22 English
Trading Halt 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a market release dated 23-24 August 2010 from Phylogica Limited regarding a trading halt requested by the company pending an announcement. It mentions the company is undertaking a capital raising and requests the halt until the announcement or normal trading resumes. There are no financial statements, detailed financial data, or report contents included. The document is short (2194 characters) and serves as an announcement about a trading halt related to capital raising activities. This fits the category of Capital/Financing Update (CAP) rather than a full report or regulatory filing. Therefore, the classification is CAP with high confidence.
2010-08-22 English
Finance News Network Interview with Director Nick Woolf 5 pages ?Kb
Call Transcript Classification · 95% confidence The document is a transcript of an interview with a company director discussing the company's business model, partnerships, drug discovery programs, recent collaborations, stock exchange listings, and funding status. It is a detailed conversation rather than a formal financial report or regulatory filing. There are no financial statements, earnings highlights, or formal announcements of voting results or management changes. The content is primarily an investor update in a conversational format, typical of a call transcript or interview transcript. Given the detailed Q&A format and the nature of the content, this fits best as a Call Transcript (CT). The document length (over 10,000 characters) supports it being a full transcript rather than a brief announcement or summary.
2010-08-18 English
Bioshares CEO Interview P Watt 6 pages ?Kb
Call Transcript Classification · 95% confidence The document is an investor briefing transcript dated August 19, 2010, featuring a detailed discussion with the CEO and a Non-Executive Director of Phylogica. It focuses on recent business developments, specifically a new pharmaceutical drug discovery collaboration deal with MedImmune (AstraZeneca), including financial terms, business model changes, and strategic outlook. The content is a full transcript of a company presentation or briefing to investors, discussing business strategy, deal specifics, and company prospects. It is not a formal regulatory filing, annual or quarterly report, earnings release, or audit report. It is not a short announcement or notice but a detailed transcript of a company communication event. Therefore, the document best fits the category of a Call Transcript (CT), which includes full text transcripts of company conference calls or investor briefings with Q&A and detailed discussion.
2010-08-18 English
Reinstatement to Official Quotation 1 page ?Kb
Delisting Announcement Classification · 95% confidence The document is a market release announcing the reinstatement of trading (lifting of suspension) of the company's securities on the exchange. It is an official notice related to the company's stock listing status, not a financial report or detailed filing. The content is brief and focused on the trading status, which fits the definition of a Delisting Announcement or its reverse (reinstatement). Since the document announces the lifting of suspension (reinstatement to official quotation), it aligns best with the Delisting Announcement category, which covers official notices about stock exchange status changes. Confidence is high due to the clear and specific nature of the announcement.
2010-08-17 English
Phylogica Signs Agreement with MedImmune / AstraZeneca 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing agreement between Phylogica Ltd and MedImmune for antimicrobial peptide discovery. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed investor presentation. It is a corporate announcement about a business collaboration and licensing deal. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to a strategic partnership and potential future revenue streams through licensing and milestone payments. The document length is about 5122 characters, which is consistent with a press release rather than a full report. Therefore, the classification is CAP with high confidence.
2010-08-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.